![]() |
Name |
Oxaflumazine disuccinate
|
Molecular Formula | C34H44F3N3O10S | |
IUPAC Name* |
butanedioic acid;10-[3-[4-[2-(1,3-dioxan-2-yl)ethyl]piperazin-1-yl]propyl]-2-(trifluoromethyl)phenothiazine
|
|
SMILES |
C1COC(OC1)CCN2CCN(CC2)CCCN3C4=CC=CC=C4SC5=C3C=C(C=C5)C(F)(F)F.C(CC(=O)O)C(=O)O.C(CC(=O)O)C(=O)O
|
|
InChI |
InChI=1S/C26H32F3N3O2S.2C4H6O4/c27-26(28,29)20-7-8-24-22(19-20)32(21-5-1-2-6-23(21)35-24)11-3-10-30-13-15-31(16-14-30)12-9-25-33-17-4-18-34-25;2*5-3(6)1-2-4(7)8/h1-2,5-8,19,25H,3-4,9-18H2;2*1-2H2,(H,5,6)(H,7,8)
|
|
InChIKey |
GGEQGDSOSYWSPU-UHFFFAOYSA-N
|
|
Synonyms |
Oxaflumazine disuccinate; Oxaflumine; 7450-97-7; Oxaflumazine succinate; SD 270-31; JP68P9753Z; butanedioic acid;10-[3-[4-[2-(1,3-dioxan-2-yl)ethyl]piperazin-1-yl]propyl]-2-(trifluoromethyl)phenothiazine; EINECS 231-219-1; UNII-JP68P9753Z; DTXSID30225502; OXAFLUMAZINE DISUCCINATE [MI]; Phenothiazine, 10-(3-(4-(2-m-dioxan-2-ylethyl)-1-piperazinyl)propyl)-2-(trifluoromethyl)-, disuccinate; Succinic acid, compound with 10-(3-(4-(2-(1,3-dioxan-2-yl)ethyl)piperazin-1-yl)propyl)-2-(trifluoromethyl)-10H-phenothiazine (2:1); SD-270-31; Q27281624; 10-(3-(4-(2-(1,3-DIOXAN-2-YL)ETHYL)-1-PIPERAZINYL)PROPYL)-2-(TRIFLUOROMETHYL)-10H-PHENOTHIAZINE, DISUCCINATE
|
|
CAS | 7450-97-7 | |
PubChem CID | 81955 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 743.8 | ALogp: | 5.3 |
HBD: | 4 | HBA: | 17 |
Rotatable Bonds: | 13 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 203.0 | Aromatic Rings: | 5 |
Heavy Atoms: | 51 | QED Weighted: | 0.2 |
Caco-2 Permeability: | -5.133 | MDCK Permeability: | 0.00001340 |
Pgp-inhibitor: | 0.999 | Pgp-substrate: | 0.988 |
Human Intestinal Absorption (HIA): | 0.002 | 20% Bioavailability (F20%): | 0.983 |
30% Bioavailability (F30%): | 0.926 |
Blood-Brain-Barrier Penetration (BBB): | 0.995 | Plasma Protein Binding (PPB): | 93.33% |
Volume Distribution (VD): | 2.294 | Fu: | 3.25% |
CYP1A2-inhibitor: | 0.126 | CYP1A2-substrate: | 0.287 |
CYP2C19-inhibitor: | 0.195 | CYP2C19-substrate: | 0.962 |
CYP2C9-inhibitor: | 0.019 | CYP2C9-substrate: | 0.166 |
CYP2D6-inhibitor: | 0.982 | CYP2D6-substrate: | 0.885 |
CYP3A4-inhibitor: | 0.154 | CYP3A4-substrate: | 0.906 |
Clearance (CL): | 13.56 | Half-life (T1/2): | 0.002 |
hERG Blockers: | 0.993 | Human Hepatotoxicity (H-HT): | 0.716 |
Drug-inuced Liver Injury (DILI): | 0.404 | AMES Toxicity: | 0.041 |
Rat Oral Acute Toxicity: | 0.622 | Maximum Recommended Daily Dose: | 0.873 |
Skin Sensitization: | 0.555 | Carcinogencity: | 0.253 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.008 |
Respiratory Toxicity: | 0.962 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001488 | ![]() |
0.211 | D0P5SA | ![]() |
0.562 | ||
ENC004066 | ![]() |
0.205 | D03NTJ | ![]() |
0.520 | ||
ENC001325 | ![]() |
0.197 | D0R4OM | ![]() |
0.500 | ||
ENC002115 | ![]() |
0.196 | D01QML | ![]() |
0.468 | ||
ENC005326 | ![]() |
0.196 | D0L0MB | ![]() |
0.468 | ||
ENC003576 | ![]() |
0.195 | D02HED | ![]() |
0.454 | ||
ENC003524 | ![]() |
0.188 | D0B2UZ | ![]() |
0.396 | ||
ENC004494 | ![]() |
0.184 | D0AO6B | ![]() |
0.395 | ||
ENC002014 | ![]() |
0.183 | D0Y0ER | ![]() |
0.390 | ||
ENC004716 | ![]() |
0.183 | D05NOS | ![]() |
0.375 |